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Summary.-Serial serum diphenylhydantoin and urinary 5-(p-hydroxyphenyl)-5-
phenylhydantoin concentrations were determined in 8 patients with malignant
disease and 4 healthy volunteers on 2 separate occasions after an oral dose of
diphenylhydantoin (500 mg). No significant difference was observed between
metabolism before and 10 days after immunization with BCG or Corynebacterium
parvum. Volunteers without intervening immunization similarly showed no
difference.
IMMUNOTHERAPY is being increasingly
used in the treatment of patients with
malignant neoplasia. Two commonly used
immunotherapeutic agents, Bacillus Cal-
mette-Guerin (BCG) and Corynebacterium
parvum (C. parvum) have, however, been
shown to suppress the hepatic metabolism
of drugs in animals (Farqhuar et al., 1975;
Soyka et al., 1976). As chemotherapy may
be administered concurrently with im-
munotherapy, and as some cytotoxic
drugs depend on hepatic enzymes for
activation or detoxification, we elected to
study the influence ofBOG and C. parvum
on hepatic drug hydroxylation in man.
MATERIALS AND METHODS
Subjects.-8 patients with disseminated
malignancy were studied, after informed con-
sent had been obtained. No patient had
received previous radiotherapy or chemo-
immunotherapy; other clinical details are
shown in Table I. Liver function, as judged
by routine biochemical and radiolabelled
isotopic screening, was normal. Four healthy
volunteers were also included in the study.
Immunization.-BCG vaccine (percu-
taneous Glaxo) was reconstituted with 0 3 ml
sterile water (average number of organisms
1-5 x 108) and administered by "multiple
puncture gun". Five applications of vaccine
(100needlepunctures 2 mm depth) were given
in each limb.
C. parvum (Burroughs-Wellcome CN6 134)
2 mg/M2 was given in 300 ml of saline over
3 h by i.v. infusion.
Study protocol. - Diphenylhydantoin
(Phenytoin, Parke-Davis) 500 mg orally was
given at 1100 p.m. on Day 1 on an empty
stomach. Blood samples were collected at 10,
14, 18, 22, 34, 38, 42, 46 and 58 h later. Three
consecutive 24h urine samples were also
collected.
Alternate patients were then immunized
with BCG or C. parvum immediately after the
last venepuncture. A second dose of pheny-
toin was given 10 days later and serum and
urine samples collected as described, each
patient acting as his/her own control. The 4
volunteers similarly had 2 single-dose pheny-
toin tests 10 days apart but without inter-
vening immunotherapy.
Drug estimations.-Serum: Serum concen-
trations were determined by gas chromato-
graphy using a modification of the method of
MacGee (1970).
Urine: Urinary concentrations of pheny-
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toin and 5-(p-hydroxyphenyl)-5-phenylhy-
dantoin (p-HHH) were determined by high-
pressure liquid chromatography using a
modification of the procedure described by
Kabra & Marton (1976).
An aliquot of each urine sample (0.25 ml)
was acidified with 12N HCI (0-25 ml), heated in
a steam bath for 1 h, the resulting hydro-
lysate cooled, and the pH adjusted to 6-3 by
the addition of an alkaline buffer (IM
NaHCO3; 7-5M NaOH). Ethyl acetate/
dichloromethane (10 ml) (1:2, v:v) was then
added and the tube agitated for 5 min. After
centrifugation, the aqueous layer was de-
canted and the organic phase washed twice
with 3 ml 0-6M NaHCO3. The aqueous phase
was again removed, the organic phase
evaporated to dryness in a rotary evaporator
and the residue reconstituted with methanol
(250 jul) before assay.
Separation and quantiation of phenytoin
and p-HPPH was achieved with the use of a
Perkin-Elmer LC 55 liquid chromatograph
equipped with a spheresorb S 5W reverse-
phase column (10x0 46 cm). The developing
system used was water-methanol (75:25, v:v)
with a flow rate of 2 ml/min at 1000 lb/in2.
Absorption was monitored at 254 nm and
peak areas determined using an integrator
(Infrotonics CRS 309). Samples of urine
extract (5 ,ul) were applied directly to the
column. Concentrations were determined by
reference to calibration curves constructed
from authentic standards, added to urine and
extracted as described. In all instance, the
relationship between absorbance (in arbitrary
units) and drug concentrations were linear.
All samples were determined in duplicate.
Kinetic analysis.-The areas under each
concentration/time curve (AUC in mg.h/l)
from 10 to 58 h were determined by the
Trapezoidal method. The values for Km
(mg/I) and Vmax (mg/l/day) derived from
these individual curves were estimated using
Michaelis-Mentin kinetics and an iterative
computer programme.
Statistics.-Paired Student's t tests were
used to determine the within-patient varia-
tion in the derived experimental values.
RESULTS
The mean age, sex, body weight and
diagnosis of the 8 patients are given in
Table I. Six patients had metastatic
melanoma, 1 had metastatic rectal car-
TABLE I.-Details ofpatients studied
Age
Subgroup (yrs)
BCG 42
49
46
71
C. parvum 70
50
59
44
cinoma and
nephroma.
The areas
Sex
M
F
M
F
M
F
M
M
Wt.
(kg)
71
47
67
60
58
76
78
67
Diagnosis
(all metastatic)
Malignant melanoma
Malignant melanoma
Rectal carcinoma
Malignant melanoma
Hypernephroma
Malignant melanoma
Malignant melanoma
Malignant melanoma
1 had metastatic hyper-
beneath the concentration/
time curve, values for Km and Vmax are
given in Table II. No within-subject
difference was found in the healthy
volunteers or the patients. There was,
however, a significant difference in the
AUC and Km values between healthy
volunteers and patients (Table II).
The proportion ofthe administered dose
excreted in the urine as p-HPPH during
the first 72 h after administration is given
in Table III. No difference was found
between the 2 tests in healthy volunteers
or patients. It was noted that the subjects
who excreted the major proportion of the
TABLE II.-Comparison of AUC (mg.h/l), Km (mg/l) and Vmax (mg/l/day)
(mean±s.e.) before (Day 1) and after (Day 10) immunotherapy
A.U.C. (mg.h/l) Km (mg/1)
t AA
Vmax (mg/l/day)
Subgroup Day 1 10 1 10 1 10
Control 272+41 263+35 11-1±1-9 10-4±1-5 11-841-6 10-9±1-0
BCG **148±27 142+31 *6-1±0-7 5-9±1-0 8-4±1-1 9-1±0-6
C. parvum **94±19 85±19 **4-2±0-9 3-8±0-8 6-8±2-0 6-4+2-2
Significant difference between control subjects and patients receiving BCG or C. parvum are indicated by
* (P<0-05) and ** (P<0-01) (two-tailed).
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TABLE III.-Urine excretion of 5-(p-
hydroxyphenyl)-5-phenylhydantoin (% of
administered dose) (mean±s.e., n=4)
during the first 72 h after an oral dose of
phenytoin (500 mg) before (Day 1) and
after (Day 10) immunotherapy.
Subgroup Day 1 Day 10
Control 40 7±2-2 45-4±3-8
BCG 52-9±2-9 56 ±5
C. parvum 59-7± 10-7 60-3+2-6
dose on the first day of the study did so
when the test was repeated. No difference
was seen between the healthy controls and
the patients.
DISCUSSION
Diphenylhydantoin was selected as the
test drug because the plasma half-time
correlates well with other drugs of thera-
peutic relevance, for example, amylobar-
bitone, glutethimide and sulphinpyrazone
(Brien et al., 1975). It was considered that
phenytoin was the most suitable drug for
study in this context. Though there is
suggestive evidence that chronic adminis-
tration of phenytoin in epileptic patients
may cause immunosuppression (Sorrell et
al., 1971; Sorrell & Forbes, 1975), it was
considered extremely unlikely that a single
500mg dose would produce immuno-
suppression, and there is as yet no
described relationship between immuno-
suppression and impaired hepatic metabo-
lism. Similarly, whilst chronic administra-
tion of phenytoin may produce enzyme
induction (Petruch et al., 1974) there was
no evidence ofthis in the control patients.
The decay of serum phenytoin in man is
not a simple first-order process (Arnold &
Gerber, 1970). The dose-dependent decay
is explained by saturation of the drug-
metabolizing system, and appears to
change from zero to first order as the
serum concentration decreases (Bochner
et at., 1972). Elimination can be explained
by Michaelis-Mentin kinetics (Arnold &
Gerber, 1970; Gerber & Wagner, 1972) and
a computer programme is available which
fits the serum concentration/time curve
after an oral loading dose of phenytoin
(Mawer et al., 1974). Ten hours following
such a dose, absorption is complete and
the drug is distributed within a one-
compartment open model. From such a
model values of Km and Vmax may be
calculated.
The values so derived indicate that
immunotherapy using either BCG or C.
parvum had no statistically significant
effect on the metabolism of phenytoin in
the patients studied. Similarly, no differ-
ence was seen in the proportion ofurinary
p-HPPH excreted during the first 48 h, in
both patients and healthy volunteers. One
interesting observation was the signifi-
cantly smaller values for AUC in the
patients than in the healthy volunteers.
This observation suggests that liver
metabolism may be altered in patients
with no clinical or biochemical evidence of
metastatic hepatic infiltration, an observa-
tion that may have therapeutic relevance.
Thus, immunotherapy alone does not
impair the ability of the Jiver to hydroxy-
late phenytoin and presumably, therefore,
the ability to metabolize other drugs that
are handled similarly. It is not possible to
predict from this study whether metabo-
lism would be impaired by repeated ad-
ministration of either BCG or C. parvum.
A different sampling schedule may have
detected a change, but the 10-day interval
was selected on projection from animal
data (Farquhar et al., 1975; Mosedale &
Smith, 1975) and because peak immuno-
stimulation occurs 10-14 days after im-
munotherapy (Thatcher et al., 1978).
There is, however, evidence that the con-
current administration of immunothera-
peutic stimulants and cyclophosphamide
willdepress aminopyrene N-demethylation
(Lipton et al., 1977) and therefore, caution
should be exercised when combining these
2 treatment modalities.
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